4 studies found for:    E5103
Show Display Options
Rank Status Study
1 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
2 Completed Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Conditions: Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolism;   Thromboembolism;   Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b);   Drug: low molecular weight heparin/unfractionated heparin;   Drug: warfarin
3 Active, not recruiting Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: insulin aspart (FIAsp);   Drug: insulin detemir;   Drug: insulin aspart
4 Recruiting Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
Conditions: TIA;   Stroke;   Carotid Artery Stenosis
Intervention: Radiation: PET/CT imaging with F-18 fluorodeoxyglucose

Indicates status has not been verified in more than two years